Watch this BioTech - Selling #COVID19 Hype, squeezing a small percent (19%) for shorts in the market. I am not looking to buy the hype train. Instead wait for a peak, then go Puts. (if VIX is normal by then, Buy the Puts, otherwise spread) This play will materialize in two weeks - Otherwise Expires. Visit back. This is a biotech - we wont have any cash flow....
Sage Therapeutics (NASDAQ:SAGE) announces next steps in the Landscape Program, the clinical program evaluating zuranolone (SAGE-217) for the treatment of postpartum depression (PPD) and major depressive disorder (MDD), following a Breakthrough Therapy guidance meeting with the FDA. Following discussions with the FDA, Sage plans to initiate three new short-term...
Possible gap fill above $54 with $62 as a upside target Imitated afterhours by Citi to buy Average analysts price target $95.42 | Overweight Short interest high at 13.09% Stifel analyst Paul Matteis says Sage Therapeutics shares below $50 represent one of the best opportunities in Stifel's coverage universe. The bear case is the uncertain path forward for...
Possibility of a major double top, but also the chances of a great reversal trade, its on the watchlist either way, no bias, just trade.
Yesterdays selloff may present a good opportunity to get a reversal trade, the poor trial results are quite a Mich mash but what was ignored was the fact that some of the group had actually not taken the drug dosage required. I am not medical expert so only look at this on a technical level and see a chance for a dead cat bounce at the minimum. The RSI is at all...
So What? SAGE has been on its own phase the last 2 trading days. Jan 7 - announced Phase 3 success of SAGE-217 for postpartum depression; same day AXS-05 for MDD was reported. Both drugs are being compared to each other for the future MDD treatment; promising (as usual). Axsome is a low hanging fruit with a higher volume but I do like how SAGE moves. I'll have...
About the ROBIN Study Sage’s Phase 3 ROBIN Study evaluated the efficacy, safety and pharmacokinetics of SAGE-217 in 151 adult female patients diagnosed with severe postpartum depression (PPD). The primary endpoint of the multicenter, randomized, double-blind, parallel-group, placebo-controlled study was to determine if outpatient treatment with SAGE-217 reduces...
$SAGE broke the bottom resistance trend and is now sitting directly on support. We could see 1-2 bounce attempts before a breakout
Well this baby is ready to go higher, it is making higher lows and seems very well consolidated. There is an FDA report for an expedite development of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217. This would be the final phase of trials before receiving the right to file a New Drug Application with the FDA and potentially...
This looks like a tight flag forming that might break out. What do y'all think?
Extremely bearish after a 161% jump on successful clinical trial results. Falling action predicates a new high low point for the stock and further stabilization going forward
Possible short term breakout and buy in opportunity for Sage Therapeutics. This could be bull trap which would result in a short term loss of capital, but still a highly undervalued stock at its current price. Buy.
Like this look of the hourly chart here on the pullback following the PPD test results rally.
Sage has gapped up on news and this is a good gap and go candidate watch for a break higher or a retrace and bounce look to trade stock here off of that or even options. It is a more volatile stock so have to have stomach for that
Broke the descending trend line couple of days back. Hit the top of bollinger bands and horizontal resistance and reversed. Above 54.50 definite breakout out of all the channels, best would be to consolidate between today's low and 54.30 for a few sessions and the break the resistance of 54.50 with some volume. Surely on the watchlist , can go long with today's...